Production (Stage)
Marker Therapeutics, Inc.
MRKR
$1.77
$0.2516.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 349.10K | 2.25M | 1.93M | 1.17M | 1.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 349.10K | 2.25M | 1.93M | 1.17M | 1.24M |
| Cost of Revenue | 3.14M | 5.09M | 3.47M | 2.34M | 2.58M |
| Gross Profit | -2.79M | -2.83M | -1.55M | -1.17M | -1.33M |
| SG&A Expenses | 1.37M | 1.03M | 854.70K | 1.14M | 1.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.50M | 6.11M | 4.33M | 3.48M | 3.79M |
| Operating Income | -4.16M | -3.86M | -2.40M | -2.31M | -2.55M |
| Income Before Tax | -4.45M | -3.79M | -2.31M | -2.19M | -2.39M |
| Income Tax Expenses | -- | 50.00K | -- | -- | -- |
| Earnings from Continuing Operations | -4.45M | -3.84M | -2.31M | -2.19M | -2.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.45M | -3.84M | -2.31M | -2.19M | -2.39M |
| EBIT | -4.16M | -3.86M | -2.40M | -2.31M | -2.55M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.40 | -0.42 | -0.26 | -0.25 | -0.27 |
| Normalized Basic EPS | -0.22 | -0.26 | -0.16 | -0.15 | -0.17 |
| EPS Diluted | -0.40 | -0.42 | -0.26 | -0.25 | -0.27 |
| Normalized Diluted EPS | -0.22 | -0.26 | -0.16 | -0.15 | -0.17 |
| Average Basic Shares Outstanding | 11.11M | 9.18M | 8.92M | 8.92M | 8.90M |
| Average Diluted Shares Outstanding | 11.11M | 9.18M | 8.92M | 8.92M | 8.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |